Hispana. Acceso en línea al Patrimonio Cultural Digital Español

Está en:  › Erregistro

A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia

Identificadores del recurso

http://hdl.handle.net/10803/403440

Jatorria

(Tesis de la Universitat Internacional de Catalunya)

Fitxa

Izenburu:: A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia
Tema:: Alopecia; Androgenetic alopecia; Hair loss; Platelet-rich plasma; Growth factors; Double-blind; Clinical trial; Drug therapy; Humans; Dermatología; 616.5
Deskribapen:: Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.
Iturri:: TDX (Tesis Doctorals en Xarxa)
Idioma:: English
Autor/Productor:: Rubina Filipa Ascensão, Alves
Argitaratzaile:: Universitat Internacional de Catalunya
Otros colaboradores/productores:: Grimalt, Ramon; Universitat Internacional de Catalunya. Departament de Medicina
Eskubideak:: L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/; info:eu-repo/semantics/openAccess
Data:: 2017-02-17
Tipo de recurso:: info:eu-repo/semantics/doctoralThesis; info:eu-repo/semantics/publishedVersion
Formatu:: application/pdf; 258 p.

oai_dc

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
1. <dc:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</dc:title>
2. <dc:creator>Rubina Filipa Ascensão, Alves</dc:creator>
3. <dc:contributor>Grimalt, Ramon</dc:contributor>
4. <dc:contributor>Universitat Internacional de Catalunya. Departament de Medicina</dc:contributor>
5. <dc:subject>Alopecia</dc:subject>
6. <dc:subject>Androgenetic alopecia</dc:subject>
7. <dc:subject>Hair loss</dc:subject>
8. <dc:subject>Platelet-rich plasma</dc:subject>
9. <dc:subject>Growth factors</dc:subject>
10. <dc:subject>Double-blind</dc:subject>
11. <dc:subject>Clinical trial</dc:subject>
12. <dc:subject>Drug therapy</dc:subject>
13. <dc:subject>Humans</dc:subject>
14. <dc:subject>Dermatología</dc:subject>
15. <dc:subject>616.5</dc:subject>
16. <dc:description>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</dc:description>
17. <dc:date>2017-02-17</dc:date>
18. <dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
19. <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
20. <dc:identifier>http://hdl.handle.net/10803/403440</dc:identifier>
21. <dc:language>eng</dc:language>
22. <dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
23. <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
24. <dc:format>application/pdf</dc:format>
25. <dc:format>258 p.</dc:format>
26. <dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
27. <dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
</oai_dc:dc>

dim

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
1. <dim:field element="contributor" mdschema="dc">Universitat Internacional de Catalunya. Departament de Medicina</dim:field>
2. <dim:field element="contributor" mdschema="dc" qualifier="author">Rubina Filipa Ascensão, Alves</dim:field>
3. <dim:field element="contributor" lang="en_US" mdschema="dc" qualifier="authoremail">rubinaalves@gmail.com</dim:field>
4. <dim:field element="contributor" lang="en_US" mdschema="dc" qualifier="authoremailshow">true</dim:field>
5. <dim:field element="contributor" mdschema="dc" qualifier="director">Grimalt, Ramon</dim:field>
6. <dim:field element="contributor" lang="en_US" mdschema="dc" qualifier="authorsendemail">true</dim:field>
7. <dim:field element="date" mdschema="dc" qualifier="accessioned">2017-05-25T17:42:38Z</dim:field>
8. <dim:field element="date" mdschema="dc" qualifier="available">2017-05-25T17:42:38Z</dim:field>
9. <dim:field element="date" mdschema="dc" qualifier="issued">2017-02-17</dim:field>
10. <dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10803/403440</dim:field>
11. <dim:field element="description" lang="en_US" mdschema="dc" qualifier="abstract">Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</dim:field>
12. <dim:field element="format" lang="en_US" mdschema="dc" qualifier="extent">258 p.</dim:field>
13. <dim:field element="format" mdschema="dc" qualifier="mimetype">application/pdf</dim:field>
14. <dim:field element="language" lang="en_US" mdschema="dc" qualifier="iso">eng</dim:field>
15. <dim:field element="publisher" mdschema="dc">Universitat Internacional de Catalunya</dim:field>
16. <dim:field element="rights" mdschema="dc" qualifier="license">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dim:field>
17. <dim:field element="rights" mdschema="dc" qualifier="accessLevel">info:eu-repo/semantics/openAccess</dim:field>
18. <dim:field element="source" mdschema="dc">TDX (Tesis Doctorals en Xarxa)</dim:field>
19. <dim:field element="subject" lang="en_US" mdschema="dc">Alopecia</dim:field>
20. <dim:field element="subject" lang="en_US" mdschema="dc">Androgenetic alopecia</dim:field>
21. <dim:field element="subject" lang="en_US" mdschema="dc">Hair loss</dim:field>
22. <dim:field element="subject" lang="en_US" mdschema="dc">Platelet-rich plasma</dim:field>
23. <dim:field element="subject" lang="en_US" mdschema="dc">Growth factors</dim:field>
24. <dim:field element="subject" lang="en_US" mdschema="dc">Double-blind</dim:field>
25. <dim:field element="subject" lang="en_US" mdschema="dc">Clinical trial</dim:field>
26. <dim:field element="subject" lang="en_US" mdschema="dc">Drug therapy</dim:field>
27. <dim:field element="subject" lang="en_US" mdschema="dc">Humans</dim:field>
28. <dim:field element="subject" lang="en_US" mdschema="dc" qualifier="other">Dermatología</dim:field>
29. <dim:field element="subject" lang="en_US" mdschema="dc" qualifier="udc">616.5</dim:field>
30. <dim:field element="title" lang="en_US" mdschema="dc">A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</dim:field>
31. <dim:field element="type" mdschema="dc">info:eu-repo/semantics/doctoralThesis</dim:field>
32. <dim:field element="type" mdschema="dc">info:eu-repo/semantics/publishedVersion</dim:field>
33. <dim:field element="embargo" lang="en_US" mdschema="dc" qualifier="terms">cap</dim:field>
</dim:dim>

etdms

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
1. <title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</title>
2. <creator>Rubina Filipa Ascensão, Alves</creator>
3. <contributor>rubinaalves@gmail.com</contributor>
4. <contributor>true</contributor>
5. <contributor>Grimalt, Ramon</contributor>
6. <contributor>true</contributor>
7. <subject>Alopecia</subject>
8. <subject>Androgenetic alopecia</subject>
9. <subject>Hair loss</subject>
10. <subject>Platelet-rich plasma</subject>
11. <subject>Growth factors</subject>
12. <subject>Double-blind</subject>
13. <subject>Clinical trial</subject>
14. <subject>Drug therapy</subject>
15. <subject>Humans</subject>
16. <description>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</description>
17. <date>2017-05-25</date>
18. <date>2017-05-25</date>
19. <date>2017-02-17</date>
20. <type>info:eu-repo/semantics/doctoralThesis</type>
21. <type>info:eu-repo/semantics/publishedVersion</type>
22. <identifier>http://hdl.handle.net/10803/403440</identifier>
23. <language>eng</language>
24. <rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</rights>
25. <rights>info:eu-repo/semantics/openAccess</rights>
26. <publisher>Universitat Internacional de Catalunya</publisher>
27. <source>TDX (Tesis Doctorals en Xarxa)</source>
</thesis>

marc

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
1. <leader>00925njm 22002777a 4500</leader>
2. <datafield ind1=" " ind2=" " tag="042">
  1. <subfield code="a">dc</subfield>
  </datafield>
3. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Rubina Filipa Ascensão, Alves</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
4. <datafield ind1=" " ind2=" " tag="260">
  1. <subfield code="c">2017-02-17</subfield>
  </datafield>
5. <datafield ind1=" " ind2=" " tag="520">
  1. <subfield code="a">Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</subfield>
  </datafield>
6. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">http://hdl.handle.net/10803/403440</subfield>
  </datafield>
7. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Alopecia</subfield>
  </datafield>
8. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Androgenetic alopecia</subfield>
  </datafield>
9. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Hair loss</subfield>
  </datafield>
10. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Platelet-rich plasma</subfield>
  </datafield>
11. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Growth factors</subfield>
  </datafield>
12. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Double-blind</subfield>
  </datafield>
13. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Clinical trial</subfield>
  </datafield>
14. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Drug therapy</subfield>
  </datafield>
15. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Humans</subfield>
  </datafield>
16. <datafield ind1="0" ind2="0" tag="245">
  1. <subfield code="a">A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</subfield>
  </datafield>
</record>

marc_ccuc

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
1. <leader>nam a 5i 4500</leader>
2. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Alopecia</subfield>
  </datafield>
3. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Androgenetic alopecia</subfield>
  </datafield>
4. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Hair loss</subfield>
  </datafield>
5. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Platelet-rich plasma</subfield>
  </datafield>
6. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Growth factors</subfield>
  </datafield>
7. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Double-blind</subfield>
  </datafield>
8. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Clinical trial</subfield>
  </datafield>
9. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Drug therapy</subfield>
  </datafield>
10. <datafield ind1=" " ind2=" " tag="653">
  1. <subfield code="a">Humans</subfield>
  </datafield>
11. <datafield ind1="1" ind2="0" tag="245">
  1. <subfield code="a">A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</subfield>
  </datafield>
12. <datafield ind1=" " ind2="1" tag="264">
  1. <subfield code="a">[Barcelona] :</subfield>
  2. <subfield code="b">Universitat Internacional de Catalunya,</subfield>
  3. <subfield code="c">2017</subfield>
  </datafield>
13. <datafield ind1="4" ind2="0" tag="856">
  1. <subfield code="z">Accés lliure</subfield>
  2. <subfield code="u">http://hdl.handle.net/10803/403440</subfield>
  </datafield>
14. <controlfield tag="007">cr |||||||||||</controlfield>
15. <controlfield tag="008">AAMMDDs2017 sp ||||fsm||||0|| 0 eng|c</controlfield>
16. <datafield ind1="1" ind2=" " tag="100">
  1. <subfield code="a">Rubina Filipa Ascensão, Alves,</subfield>
  2. <subfield code="e">autor</subfield>
  </datafield>
17. <datafield ind1=" " ind2=" " tag="300">
  1. <subfield code="a">1 recurs en línia (258 pàgines)</subfield>
  </datafield>
18. <datafield ind1=" " ind2=" " tag="502">
  1. <subfield code="g">Tesi</subfield>
  2. <subfield code="b">Doctorat</subfield>
  3. <subfield code="c">Universitat Internacional de Catalunya. Departament de Medicina</subfield>
  4. <subfield code="d">2017</subfield>
  </datafield>
19. <datafield ind1="2" ind2=" " tag="710">
  1. <subfield code="a">Universitat Internacional de Catalunya. Departament de Medicina</subfield>
  </datafield>
20. <datafield ind1=" " ind2="4" tag="655">
  1. <subfield code="a">Tesis i dissertacions electròniques</subfield>
  </datafield>
21. <datafield ind1="1" ind2=" " tag="700">
  1. <subfield code="a">Grimalt, Ramon,</subfield>
  2. <subfield code="e">supervisor acadèmic</subfield>
  </datafield>
22. <datafield ind1="0" ind2=" " tag="730">
  1. <subfield code="a">TDX</subfield>
  </datafield>
23. <datafield ind1=" " ind2=" " tag="520">
  1. <subfield code="a">Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</subfield>
  </datafield>
24. <datafield ind1=" " ind2=" " tag="998">
  1. <subfield code="a">si</subfield>
  </datafield>
25. <datafield ind1=" " ind2=" " tag="040">
  1. <subfield code="a">ES-BaCBU</subfield>
  2. <subfield code="b">cat</subfield>
  3. <subfield code="e">rda</subfield>
  4. <subfield code="c">ES-BaCBU</subfield>
  </datafield>
26. <datafield ind1=" " ind2=" " tag="336">
  1. <subfield code="a">text</subfield>
  2. <subfield code="b">txt</subfield>
  3. <subfield code="2">rdacontent</subfield>
  </datafield>
27. <datafield ind1=" " ind2=" " tag="337">
  1. <subfield code="a">informàtic</subfield>
  2. <subfield code="b">c</subfield>
  3. <subfield code="2">rdamedia</subfield>
  </datafield>
28. <datafield ind1=" " ind2=" " tag="338">
  1. <subfield code="a">recurs en línia</subfield>
  2. <subfield code="b">cr</subfield>
  3. <subfield code="2">rdacarrier</subfield>
  </datafield>
</record>

mets

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<mets ID=" DSpace_ITEM_10803-403440" OBJID=" hdl:10803/403440" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
1. <metsHdr CREATEDATE="2022-08-14T16:56:36Z">
  1. <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
    1. <name>TDX</name>
    </agent>
  </metsHdr>
2. <dmdSec ID="DMD_10803_403440">
  1. <mdWrap MDTYPE="MODS">
    1. <xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
      1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Rubina Filipa Ascensão, Alves</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">authoremail</mods:roleTerm>
        </mods:role>
        <mods:namePart>rubinaalves@gmail.com</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">authoremailshow</mods:roleTerm>
        </mods:role>
        <mods:namePart>true</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">director</mods:roleTerm>
        </mods:role>
        <mods:namePart>Grimalt, Ramon</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">authorsendemail</mods:roleTerm>
        </mods:role>
        <mods:namePart>true</mods:namePart>
        </mods:name>
        <mods:extension>
        <mods:dateAccessioned encoding="iso8601">2017-05-25T17:42:38Z</mods:dateAccessioned>
        </mods:extension>
        <mods:extension>
        <mods:dateAvailable encoding="iso8601">2017-05-25T17:42:38Z</mods:dateAvailable>
        </mods:extension>
        <mods:originInfo>
        <mods:dateIssued encoding="iso8601">2017-02-17</mods:dateIssued>
        </mods:originInfo>
        <mods:identifier type="uri">http://hdl.handle.net/10803/403440</mods:identifier>
        <mods:abstract>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</mods:abstract>
        <mods:language>
        <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
        </mods:language>
        <mods:accessCondition type="useAndReproduction" />
        <mods:subject>
        <mods:topic>Alopecia</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Androgenetic alopecia</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Hair loss</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Platelet-rich plasma</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Growth factors</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Double-blind</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Clinical trial</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Drug therapy</mods:topic>
        </mods:subject>
        <mods:subject>
        <mods:topic>Humans</mods:topic>
        </mods:subject>
        <mods:titleInfo>
        <mods:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</mods:title>
        </mods:titleInfo>
        <mods:genre>info:eu-repo/semantics/doctoralThesis</mods:genre>
        </mods:mods>
      </xmlData>
    </mdWrap>
  </dmdSec>
3. <amdSec ID="FO_10803_403440_1">
  1. <techMD ID="TECH_O_10803_403440_1">
    1. <mdWrap MDTYPE="PREMIS">
      1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
        <premis:premis>
        <premis:object>
        <premis:objectIdentifier>
        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
        <premis:objectIdentifierValue>http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf</premis:objectIdentifierValue>
        </premis:objectIdentifier>
        <premis:objectCategory>File</premis:objectCategory>
        <premis:objectCharacteristics>
        <premis:fixity>
        <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
        <premis:messageDigest>ee3249b5cd0e76da56cf727886a93a3d</premis:messageDigest>
        </premis:fixity>
        <premis:size>28229950</premis:size>
        <premis:format>
        <premis:formatDesignation>
        <premis:formatName>application/pdf</premis:formatName>
        </premis:formatDesignation>
        </premis:format>
        </premis:objectCharacteristics>
        <premis:originalName>Tesi Rubina Filipa Alves.pdf</premis:originalName>
        </premis:object>
        </premis:premis>
        </xmlData>
      </mdWrap>
    </techMD>
  </amdSec>
4. <fileSec>
  1. <fileGrp USE="ORIGINAL">
    1. <file ADMID="FO_10803_403440_1" CHECKSUM="ee3249b5cd0e76da56cf727886a93a3d" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10803_403440_1" ID="BITSTREAM_ORIGINAL_10803_403440_1" MIMETYPE="application/pdf" SEQ="1" SIZE="28229950">
      1. <FLocat LOCTYPE="URL" href="http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf" type="simple" />
      </file>
    </fileGrp>
  </fileSec>
5. <structMap LABEL="DSpace Object" TYPE="LOGICAL">
  1. <div ADMID="DMD_10803_403440" TYPE="DSpace Object Contents">
    1. <div TYPE="DSpace BITSTREAM">
      1. <fptr FILEID="BITSTREAM_ORIGINAL_10803_403440_1" />
      </div>
    </div>
  </structMap>
</mets>

mods

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
1. <mods:name>
  1. <mods:namePart>Rubina Filipa Ascensão, Alves</mods:namePart>
  </mods:name>
2. <mods:extension>
  1. <mods:dateAvailable encoding="iso8601">2017-05-25T17:42:38Z</mods:dateAvailable>
  </mods:extension>
3. <mods:extension>
  1. <mods:dateAccessioned encoding="iso8601">2017-05-25T17:42:38Z</mods:dateAccessioned>
  </mods:extension>
4. <mods:originInfo>
  1. <mods:dateIssued encoding="iso8601">2017-02-17</mods:dateIssued>
  </mods:originInfo>
5. <mods:identifier type="uri">http://hdl.handle.net/10803/403440</mods:identifier>
6. <mods:abstract>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</mods:abstract>
7. <mods:language>
  1. <mods:languageTerm>eng</mods:languageTerm>
  </mods:language>
8. <mods:accessCondition type="useAndReproduction">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</mods:accessCondition>
9. <mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
10. <mods:subject>
  1. <mods:topic>Alopecia</mods:topic>
  </mods:subject>
11. <mods:subject>
  1. <mods:topic>Androgenetic alopecia</mods:topic>
  </mods:subject>
12. <mods:subject>
  1. <mods:topic>Hair loss</mods:topic>
  </mods:subject>
13. <mods:subject>
  1. <mods:topic>Platelet-rich plasma</mods:topic>
  </mods:subject>
14. <mods:subject>
  1. <mods:topic>Growth factors</mods:topic>
  </mods:subject>
15. <mods:subject>
  1. <mods:topic>Double-blind</mods:topic>
  </mods:subject>
16. <mods:subject>
  1. <mods:topic>Clinical trial</mods:topic>
  </mods:subject>
17. <mods:subject>
  1. <mods:topic>Drug therapy</mods:topic>
  </mods:subject>
18. <mods:subject>
  1. <mods:topic>Humans</mods:topic>
  </mods:subject>
19. <mods:titleInfo>
  1. <mods:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</mods:title>
  </mods:titleInfo>
20. <mods:genre>info:eu-repo/semantics/doctoralThesis</mods:genre>
21. <mods:genre>info:eu-repo/semantics/publishedVersion</mods:genre>
</mods:mods>

ore

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
1. <atom:id>http://hdl.handle.net/10803/403440/ore.xml</atom:id>
2. <atom:link href="http://hdl.handle.net/10803/403440" rel="alternate" />
3. <atom:link href="http://hdl.handle.net/10803/403440/ore.xml" rel="http://www.openarchives.org/ore/terms/describes" />
4. <atom:link href="http://hdl.handle.net/10803/403440/ore.xml#atom" rel="self" type="application/atom+xml" />
5. <atom:published>2017-05-25T17:42:38Z</atom:published>
6. <atom:updated>2017-05-25T17:42:38Z</atom:updated>
7. <atom:source>
  1. <atom:generator>TDX</atom:generator>
  </atom:source>
8. <atom:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</atom:title>
9. <atom:author>
  1. <atom:name>Rubina Filipa Ascensão, Alves</atom:name>
  </atom:author>
10. <atom:category label="Aggregation" scheme="http://www.openarchives.org/ore/terms/" term="http://www.openarchives.org/ore/terms/Aggregation" />
11. <atom:category scheme="http://www.openarchives.org/ore/atom/modified" term="2017-05-25T17:42:38Z" />
12. <atom:category label="DSpace Item" scheme="http://www.dspace.org/objectModel/" term="DSpaceItem" />
13. <atom:link href="http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf" length="28229950" rel="http://www.openarchives.org/ore/terms/aggregates" title="Tesi Rubina Filipa Alves.pdf" type="application/pdf" />
14. <oreatom:triples>
  1. <rdf:Description about="http://hdl.handle.net/10803/403440/ore.xml#atom">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceItem" />
    2. <dcterms:modified>2017-05-25T17:42:38Z</dcterms:modified>
    </rdf:Description>
  2. <rdf:Description about="http://www.tdx.cat/bitstream/10803/403440/5/Tesi%20Rubina%20Filipa%20Alves.pdf.xml">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>MEDIA_DOCUMENT</dcterms:description>
    </rdf:Description>
  3. <rdf:Description about="http://www.tdx.cat/bitstream/10803/403440/2/license_url">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>CC-LICENSE</dcterms:description>
    </rdf:Description>
  4. <rdf:Description about="http://www.tdx.cat/bitstream/10803/403440/3/license_text">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>CC-LICENSE</dcterms:description>
    </rdf:Description>
  5. <rdf:Description about="http://www.tdx.cat/bitstream/10803/403440/4/license_rdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>CC-LICENSE</dcterms:description>
    </rdf:Description>
  6. <rdf:Description about="http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>ORIGINAL</dcterms:description>
    </rdf:Description>
  </oreatom:triples>
</atom:entry>

qdc

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
1. <dc:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</dc:title>
2. <dc:creator>Rubina Filipa Ascensão, Alves</dc:creator>
3. <dc:contributor>Grimalt, Ramon</dc:contributor>
4. <dc:subject>Alopecia</dc:subject>
5. <dc:subject>Androgenetic alopecia</dc:subject>
6. <dc:subject>Hair loss</dc:subject>
7. <dc:subject>Platelet-rich plasma</dc:subject>
8. <dc:subject>Growth factors</dc:subject>
9. <dc:subject>Double-blind</dc:subject>
10. <dc:subject>Clinical trial</dc:subject>
11. <dc:subject>Drug therapy</dc:subject>
12. <dc:subject>Humans</dc:subject>
13. <dcterms:abstract>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</dcterms:abstract>
14. <dcterms:dateAccepted>2017-05-25T17:42:38Z</dcterms:dateAccepted>
15. <dcterms:available>2017-05-25T17:42:38Z</dcterms:available>
16. <dcterms:created>2017-05-25T17:42:38Z</dcterms:created>
17. <dcterms:issued>2017-02-17</dcterms:issued>
18. <dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
19. <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
20. <dc:identifier>http://hdl.handle.net/10803/403440</dc:identifier>
21. <dc:language>eng</dc:language>
22. <dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
23. <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
24. <dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
25. <dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
</qdc:qualifieddc>

rdf

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
1. <ow:Publication about="oai:www.tdx.cat:10803/403440">
  1. <dc:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</dc:title>
  2. <dc:creator>Rubina Filipa Ascensão, Alves</dc:creator>
  3. <dc:contributor>rubinaalves@gmail.com</dc:contributor>
  4. <dc:contributor>true</dc:contributor>
  5. <dc:contributor>Grimalt, Ramon</dc:contributor>
  6. <dc:contributor>true</dc:contributor>
  7. <dc:subject>Alopecia</dc:subject>
  8. <dc:subject>Androgenetic alopecia</dc:subject>
  9. <dc:subject>Hair loss</dc:subject>
  10. <dc:subject>Platelet-rich plasma</dc:subject>
  11. <dc:subject>Growth factors</dc:subject>
  12. <dc:subject>Double-blind</dc:subject>
  13. <dc:subject>Clinical trial</dc:subject>
  14. <dc:subject>Drug therapy</dc:subject>
  15. <dc:subject>Humans</dc:subject>
  16. <dc:description>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</dc:description>
  17. <dc:date>2017-05-25T17:42:38Z</dc:date>
  18. <dc:date>2017-05-25T17:42:38Z</dc:date>
  19. <dc:date>2017-02-17</dc:date>
  20. <dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
  21. <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
  22. <dc:identifier>http://hdl.handle.net/10803/403440</dc:identifier>
  23. <dc:language>eng</dc:language>
  24. <dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
  25. <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  26. <dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
  27. <dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
  </ow:Publication>
</rdf:RDF>

uketd_dc

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<uketd_dc:uketddc schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
1. <dc:title>A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</dc:title>
2. <dc:creator>Rubina Filipa Ascensão, Alves</dc:creator>
3. <dcterms:abstract>Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</dcterms:abstract>
4. <uketdterms:institution>Universitat Internacional de Catalunya</uketdterms:institution>
5. <dcterms:issued>2017-02-17</dcterms:issued>
6. <dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
7. <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
8. <dc:language type="dcterms:ISO639-2">eng</dc:language>
9. <dcterms:isReferencedBy>http://hdl.handle.net/10803/403440</dcterms:isReferencedBy>
10. <dc:identifier type="dcterms:URI">http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf</dc:identifier>
11. <uketdterms:checksum type="uketdterms:MD5">ee3249b5cd0e76da56cf727886a93a3d</uketdterms:checksum>
12. <uketdterms:embargodate>cap</uketdterms:embargodate>
13. <dc:subject>Alopecia</dc:subject>
14. <dc:subject>Androgenetic alopecia</dc:subject>
15. <dc:subject>Hair loss</dc:subject>
16. <dc:subject>Platelet-rich plasma</dc:subject>
17. <dc:subject>Growth factors</dc:subject>
18. <dc:subject>Double-blind</dc:subject>
19. <dc:subject>Clinical trial</dc:subject>
20. <dc:subject>Drug therapy</dc:subject>
21. <dc:subject>Humans</dc:subject>
22. <dc:subject>Dermatología</dc:subject>
</uketd_dc:uketddc>

xoai

Deskargatu XML

<?xml version="1.0" encoding="UTF-8" ?>

<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
1. <element name="dc">
  1. <element name="contributor">
    1. <element name="none">
      1. <field name="value">Universitat Internacional de Catalunya. Departament de Medicina</field>
      </element>
    2. <element name="author">
      1. <element name="none">
        <field name="value">Rubina Filipa Ascensão, Alves</field>
        </element>
      </element>
    3. <element name="authoremail">
      1. <element name="en_US">
        <field name="value">rubinaalves@gmail.com</field>
        </element>
      </element>
    4. <element name="authoremailshow">
      1. <element name="en_US">
        <field name="value">true</field>
        </element>
      </element>
    5. <element name="director">
      1. <element name="none">
        <field name="value">Grimalt, Ramon</field>
        </element>
      </element>
    6. <element name="authorsendemail">
      1. <element name="en_US">
        <field name="value">true</field>
        </element>
      </element>
    </element>
  2. <element name="date">
    1. <element name="accessioned">
      1. <element name="none">
        <field name="value">2017-05-25T17:42:38Z</field>
        </element>
      </element>
    2. <element name="available">
      1. <element name="none">
        <field name="value">2017-05-25T17:42:38Z</field>
        </element>
      </element>
    3. <element name="issued">
      1. <element name="none">
        <field name="value">2017-02-17</field>
        </element>
      </element>
    </element>
  3. <element name="identifier">
    1. <element name="uri">
      1. <element name="none">
        <field name="value">http://hdl.handle.net/10803/403440</field>
        </element>
      </element>
    </element>
  4. <element name="description">
    1. <element name="abstract">
      1. <element name="en_US">
        <field name="value">Background: Androgenetic Alopecia (AGA) is a nonscarring alopecia that affects both men and women. It is characterized by a progressive miniaturization of hair follicles with a characteristic pattern distribution in genetically predisposed men and women. The currently available treatments for AGA are sometimes perceived as having limited effectiveness, therefore, Platelet-rich plasma (PRP) has been postulated as a new therapy for AGA. Objective: To assess the efficacy of PRP on the evolution of AGA, between 6 months of treatment and baseline. Methods: This was a prospective, randomized, placebo controlled, double-blind, half-head study in male and female patients with AGA. The patient selection was performed in two different phases, according to presence or absence of medication for AGA. Group A included patients without previous medication for AGA and Group B included patients under medication for AGA (minoxidil or finasteride). All patients received a total of 3 treatments of PRP on one half-head and saline solution in the other half-head, with an interval of 1 month from each other. Injected areas comprised 4 circular areas marked with a dot tattoo. The follow-up visit was made at 6 months. Results: In Group A: administration of PRP alone attended a statistically significant improvement of mean hair density, mean terminal hair density, mean anagen hairs and telogen hairs, when compared with baseline, at 6 months. A statistically significantly correlation between demographic data and trichoscan analysis was found with two parameters: mean total hair density and mean anagen hairs. Regarding Group B: administration of PRP associated with ongoing medication is effective on the evolution of AGA. Both minoxidil or finasteride associated with PRP improved hair regrowth, although PRP in combination with minoxidil showed a greater improvement than PRP with finasteride, at six months. Limitations: The two major limitations of this study relate to the sample size and duration of follow-up. Conclusion: Administration of autologous PRP had a positive effect on male and female pattern hair loss without major side-effects.</field>
        </element>
      </element>
    </element>
  5. <element name="format">
    1. <element name="extent">
      1. <element name="en_US">
        <field name="value">258 p.</field>
        </element>
      </element>
    2. <element name="mimetype">
      1. <element name="none">
        <field name="value">application/pdf</field>
        </element>
      </element>
    </element>
  6. <element name="language">
    1. <element name="iso">
      1. <element name="en_US">
        <field name="value">eng</field>
        </element>
      </element>
    </element>
  7. <element name="publisher">
    1. <element name="none">
      1. <field name="value">Universitat Internacional de Catalunya</field>
      </element>
    </element>
  8. <element name="rights">
    1. <element name="license">
      1. <element name="none">
        <field name="value">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</field>
        </element>
      </element>
    2. <element name="accessLevel">
      1. <element name="none">
        <field name="value">info:eu-repo/semantics/openAccess</field>
        </element>
      </element>
    </element>
  9. <element name="source">
    1. <element name="none">
      1. <field name="value">TDX (Tesis Doctorals en Xarxa)</field>
      </element>
    </element>
  10. <element name="subject">
    1. <element name="en_US">
      1. <field name="value">Alopecia</field>
      2. <field name="value">Androgenetic alopecia</field>
      3. <field name="value">Hair loss</field>
      4. <field name="value">Platelet-rich plasma</field>
      5. <field name="value">Growth factors</field>
      6. <field name="value">Double-blind</field>
      7. <field name="value">Clinical trial</field>
      8. <field name="value">Drug therapy</field>
      9. <field name="value">Humans</field>
      </element>
    2. <element name="other">
      1. <element name="en_US">
        <field name="value">Dermatología</field>
        </element>
      </element>
    3. <element name="udc">
      1. <element name="en_US">
        <field name="value">616.5</field>
        </element>
      </element>
    </element>
  11. <element name="title">
    1. <element name="en_US">
      1. <field name="value">A Prospective Double-Blind Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia</field>
      </element>
    </element>
  12. <element name="type">
    1. <element name="none">
      1. <field name="value">info:eu-repo/semantics/doctoralThesis</field>
      2. <field name="value">info:eu-repo/semantics/publishedVersion</field>
      </element>
    </element>
  13. <element name="embargo">
    1. <element name="terms">
      1. <element name="en_US">
        <field name="value">cap</field>
        </element>
      </element>
    </element>
  </element>
2. <element name="bundles">
  1. <element name="bundle">
    1. <field name="name">MEDIA_DOCUMENT</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">Tesi Rubina Filipa Alves.pdf.xml</field>
        <field name="originalName">Tesi Rubina Filipa Alves.pdf.xml</field>
        <field name="description">Document Consulta</field>
        <field name="format">text/xml</field>
        <field name="size">105</field>
        <field name="url">http://www.tdx.cat/bitstream/10803/403440/5/Tesi%20Rubina%20Filipa%20Alves.pdf.xml</field>
        <field name="checksum">63ca8c149fcd06ae63e7206256aaabcf</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">5</field>
        </element>
      </element>
    </element>
  2. <element name="bundle">
    1. <field name="name">CC-LICENSE</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">license_url</field>
        <field name="originalName">license_url</field>
        <field name="format">text/plain; charset=utf-8</field>
        <field name="size">49</field>
        <field name="url">http://www.tdx.cat/bitstream/10803/403440/2/license_url</field>
        <field name="checksum">4afdbb8c545fd630ea7db775da747b2f</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">2</field>
        </element>
      2. <element name="bitstream">
        <field name="name">license_text</field>
        <field name="originalName">license_text</field>
        <field name="format">text/html; charset=utf-8</field>
        <field name="size">0</field>
        <field name="url">http://www.tdx.cat/bitstream/10803/403440/3/license_text</field>
        <field name="checksum">d41d8cd98f00b204e9800998ecf8427e</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">3</field>
        </element>
      3. <element name="bitstream">
        <field name="name">license_rdf</field>
        <field name="originalName">license_rdf</field>
        <field name="format">application/rdf+xml; charset=utf-8</field>
        <field name="size">0</field>
        <field name="url">http://www.tdx.cat/bitstream/10803/403440/4/license_rdf</field>
        <field name="checksum">d41d8cd98f00b204e9800998ecf8427e</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">4</field>
        </element>
      </element>
    </element>
  3. <element name="bundle">
    1. <field name="name">ORIGINAL</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">Tesi Rubina Filipa Alves.pdf</field>
        <field name="originalName">Tesi Rubina Filipa Alves.pdf</field>
        <field name="description" />
        <field name="format">application/pdf</field>
        <field name="size">28229950</field>
        <field name="url">http://www.tdx.cat/bitstream/10803/403440/1/Tesi%20Rubina%20Filipa%20Alves.pdf</field>
        <field name="checksum">ee3249b5cd0e76da56cf727886a93a3d</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">1</field>
        </element>
      </element>
    </element>
  </element>
3. <element name="others">
  1. <field name="handle">10803/403440</field>
  2. <field name="identifier">oai:www.tdx.cat:10803/403440</field>
  3. <field name="lastModifyDate">2017-09-13 19:53:48.092</field>
  </element>
4. <element name="repository">
  1. <field name="name">TDX</field>
  2. <field name="mail">aco@csuc.cat</field>
  </element>
</metadata>